Breaking News
Subscribe Now 0
🧐 ProPicks AI October update is out now! See which stocks made the list Pick Stocks with AI
Close

Novozymes A/S B (NVZMF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
68.3300 -3.1880    -4.46%
04/10 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 1,060
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 68.3300 - 68.3300
Novozymes B 68.3300 -3.1880 -4.46%

Novozymes A/S Company Profile

 
Get an in-depth profile of Novozymes A/S B, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryChemicals
SectorBasic Materials
Employees

10452

Equity Type

ORD

Novonesis A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novonesis A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Contact Information

Address Krogshoejvej 36
Bagsvaerd, 2880
Denmark
Phone 45 44 46 00 00
Fax -

Top Executives

Name Age Since Title
Cornelis de Jong 62 2020 Independent Chairman
Jens Obro 47 2021 Employee Representative Director
Anders Hentze Knudsen 65 2013 Employee Representative Director
Anne Breum 63 2021 Employee Representative Director
Sharon James 63 2020 Independent Director
Kevin Lane 59 2024 Director
Lise Kaae 55 2024 Director
Preben Nielsen 58 2021 Employee Representative Director
Morten Otto Alexander Sommer 43 2022 Independent Director
Kasim Kutay 59 2017 Director
Heine Dalsgaard 53 2020 Director
Jesper Brandgaard 61 2024 Vice Chair of the Board
Kim lb Sorensen - 2024 Board Observer
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NSISb Comments

Write your thoughts about Novozymes A/S
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email